Exelixis
EXEL
#1725
Rank
โ‚ฌ9.17 B
Marketcap
32,12ย โ‚ฌ
Share price
-1.16%
Change (1 day)
50.55%
Change (1 year)
Exelixis, Inc. is an American genomics-based drug discovery company and the producer of Cometriq, a treatment for medullary thyroid cancer.

Exelixis (EXEL) - Total liabilities

Total liabilities on the balance sheet as of September 2024 : โ‚ฌ0.66 Billion

According to Exelixis's latest financial reports the company's total liabilities are โ‚ฌ0.66 Billion. A companyโ€™s total liabilities is the sum of all current and non-current debts and obligations.

Exelixis - Total liabilities on balance sheet (from 2001 to 2024)

Total liabilities by year

Year Total liabilities Change
2023-12-31โ‚ฌ0.61 B12.91%
2022-12-31โ‚ฌ0.54 B51.76%
2021-12-31โ‚ฌ0.35 B70.61%
2020-12-31โ‚ฌ0.20 B17.77%
2019-12-31โ‚ฌ0.17 B51.25%
2018-12-31โ‚ฌ0.11 B-61.81%
2017-12-31โ‚ฌ0.30 B-35.89%
2016-12-31โ‚ฌ0.48 B11.26%
2015-12-31โ‚ฌ0.43 B20.13%
2014-12-31โ‚ฌ0.36 B13.82%
2013-12-31โ‚ฌ0.31 B-1.42%
2012-12-31โ‚ฌ0.32 B37.77%
2011-12-31โ‚ฌ0.23 B-47.38%
2010-12-31โ‚ฌ0.44 B25.12%
2009-12-31โ‚ฌ0.35 B8.07%
2008-12-31โ‚ฌ0.32 B46.42%
2007-12-31โ‚ฌ0.22 B-3.17%
2006-12-31โ‚ฌ0.23 B-0.64%
2005-12-31โ‚ฌ0.23 B31.04%
2004-12-31โ‚ฌ0.17 B13.78%
2003-12-31โ‚ฌ0.15 B-0.12%
2002-12-31โ‚ฌ0.15 B26.03%
2001-12-31โ‚ฌ0.12 B

Total liabilities for similar companies or competitors

Company Total liabilities differencediff. Country
โ‚ฌ57.58 B 8,614.84%๐Ÿ‡ฌ๐Ÿ‡ง UK
โ‚ฌ58.70 B 8,784.15%๐Ÿ‡ซ๐Ÿ‡ท France
โ‚ฌ70.40 B 10,555.07%๐Ÿ‡บ๐Ÿ‡ธ USA
โ‚ฌ73.77 B 11,065.83%๐Ÿ‡บ๐Ÿ‡ธ USA
โ‚ฌ80.42 B 12,071.30%๐Ÿ‡บ๐Ÿ‡ธ USA
โ‚ฌ104.32 B 15,688.55%๐Ÿ‡บ๐Ÿ‡ธ USA
โ‚ฌ122.44 B 18,432.04%๐Ÿ‡บ๐Ÿ‡ธ USA
โ‚ฌ49.4 M-92.52%๐Ÿ‡บ๐Ÿ‡ธ USA
โ‚ฌ69.83 M-89.43%๐Ÿ‡บ๐Ÿ‡ธ USA